<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353259</url>
  </required_header>
  <id_info>
    <org_study_id>2016/1512/REK nord</org_study_id>
    <secondary_id>2017-001670-42</secondary_id>
    <nct_id>NCT03353259</nct_id>
  </id_info>
  <brief_title>Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery</brief_title>
  <official_title>Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives of the study are to investigate whether adjuvant treatment in the form of&#xD;
      Tranexamic acid (Cyklokapron) and Tocilizumab (RoAcmera) to surgery in patients with chronic&#xD;
      subdural hematomaina can:&#xD;
&#xD;
        1. effectively decrease the rate of lesion recurrence requiring re-operation,&#xD;
&#xD;
        2. effectively shorten the time of lesion resolution.&#xD;
&#xD;
      Secondary objectives of the study are:1) assess the postoperative functional outcome and&#xD;
      quality of life of participants, 2) assess the postoperative mortality of participants, 3)&#xD;
      assess the treatment safety data, 4) assess the cure rate of participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoints in the study are: 1) determine postoperative recurrence requiring&#xD;
      reoperation using clinical examination and CT imaging, 2) determine the time period necessary&#xD;
      to complete healing using clinical examination and CT imaging.&#xD;
&#xD;
      Secondary endpoints in the study are: 1) to determine the functional outcome and quality of&#xD;
      life of the participants using questionnaires, 2) to determine the mortality of the&#xD;
      participants related to chronic subdural hematoma, 3) to determine the treatments&#xD;
      complications and adverse events of the participants, 4) to determine the curation using&#xD;
      clinical examination and CT imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DMC concluded that the results of 382 included patients were clear.&#xD;
  </why_stopped>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Tocilizumab (RoActemra) and Tranexamic acid (Cyklokapron) used as Adjuncts to Chronic Subdural Hematoma Surgery Regarding Postoperative Recurrence</measure>
    <time_frame>6 months period after the initial surgery.</time_frame>
    <description>To determine the rate in number and percentage of postoperative recurrence requiring re-operation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">382</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>SS-TG</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard surgery using burr-hole procedure, irrigation and drainage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SS-TXA-TG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SS-TXA-RoA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Tranexamic acid and Tocilizumab</intervention_name>
    <description>The first intervention is Tranexamic acid, The second intervention is Tocilizumab</description>
    <arm_group_label>SS-TXA-RoA</arm_group_label>
    <arm_group_label>SS-TXA-TG</arm_group_label>
    <other_name>Cyklokapron and RoActemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with informed consent, without presenting of any known contraindication for&#xD;
             the use of Tranexamic acid and Tocilizumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients or relatives who refused to consent, presenting of any known contraindication&#xD;
             for the use of Tranexamic acid and Tocilizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milo Stanisic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Milo Stanisic</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Milo Stanisic</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

